S&P DJI Announces September 2025 Quarterly Rebalance
Filed with ASX · · 7 pages · English
Arovella Therapeutics Limited on 6ix
Story so far
Earlier from Arovella Therapeutics
- Appendix 4E and Annual Report
- S&P DJI Announces March 2025 Quarterly Rebalance
- Research Agreement with University of North Carolina
- Reinstatement to Official Quotation
- Prospectus
Later from Arovella Therapeutics
- Arovella receives R&D tax rebate of $3.21 million
- CLDN18.2 CAR-T cells eliminate pancreatic cancer cells
- Positive FDA Type D Meeting Outcome
- Arovella Therapeutics appoints former CSL CSO Dr Andrew Nash as Non-executive Director
- Quarterly Activities/Appendix 4C Cash Flow Report
Follow Arovella Therapeutics into a list and get an email when it puts out news.
Follow Arovella Therapeutics